BUSINESS COMBINATIONS (Details) $ / shares in Units, $ in Thousands												12 Months Ended
	Jul. 07, 2022 USD ($) shares	Apr. 25, 2022 USD ($) shares	Jan. 27, 2022 USD ($) shares	Jan. 10, 2022 USD ($) shares	Dec. 29, 2021 USD ($) shares	Nov. 05, 2021 USD ($) $ / shares shares	Oct. 04, 2021 USD ($) shares	Aug. 02, 2021 USD ($) shares	Jul. 09, 2021 USD ($)	May 03, 2021 USD ($) shares	Apr. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) segment $ / shares	Sep. 30, 2021 USD ($) $ / shares
BUSINESS COMBINATIONS
Consideration in cash												$ 297,712	$ 41,590
Revenue												547,656	89,605
Net income (loss)												$ (337,018)	$ 10,895
Principal assumptions
Strike price | $ / shares												$ 32.56	$ 13.90
Volatility												76.62%	70.30%
Expected term												3 years 2 months 26 days	5 years 11 months 12 days
Risk-free rate												1.24%	0.93%
HistoTox Labs
BUSINESS COMBINATIONS
Consideration in cash											$ 22,389
Adjustments for net working capital											$ 68
Transaction costs													$ 576
Intangible assets												$ 8,300
Goodwill deductible for tax purposes												$ 11,014
Weighted-average estimated useful life												7 years 4 months 24 days
HistoTox Labs and Bolder BioPATH combined
BUSINESS COMBINATIONS
Number of operating segments | segment												1
Revenue												$ 35,021	11,343
Net income (loss)												2,953	2,017
Bolder BioPATH
BUSINESS COMBINATIONS
Consideration in cash										$ 17,530
Adjustments for net working capital										970
Cash and equivalents assumed										500
Reduction of seller note as part of acquisition										470
Escrowed amount										$ 1,250
Shares issued | shares										1,588,235
Common shares value										$ 34,452
Transaction costs													584
Intangible assets												12,700
Goodwill deductible for tax purposes												$ 0
Bolder BioPATH | Promissory Note
BUSINESS COMBINATIONS
Principal amount										$ 1,500
Annual interest rate										4.50%
Bolder BioPATH | Customer Relationships
BUSINESS COMBINATIONS
Weighted-average estimated useful life												8 years
Gateway Pharmacology Laboratories LLC
BUSINESS COMBINATIONS
Consideration in cash								$ 1,704
Shares issued | shares								45,323
Common shares value								$ 1,182
Transaction costs													$ 93
Intangible assets												$ 100
Goodwill deductible for tax purposes												0
BioReliance Corporation
BUSINESS COMBINATIONS
Consideration in cash									$ 175
Percentage of net sales from services to existing customers									10.00%				10.00%
Intangible assets												640
Contingent consideration													$ 175
Contingent consideration												537	640
Plato BioPharma Inc
BUSINESS COMBINATIONS
Consideration in cash							$ 10,530
Cash and equivalents assumed												1,027
Shares issued | shares							57,587
Common shares value							$ 1,776
Principal amount							$ 3,000
Intangible assets												$ 4,800
Plato BioPharma Inc | Customer Relationships
BUSINESS COMBINATIONS
Weighted-average estimated useful life												8 years
Envigo RMS Holding Corp
BUSINESS COMBINATIONS
Consideration in cash						$ 217,808
Cash and equivalents assumed												$ 2,488
Shares issued | shares						8,245,918
Common shares value						$ 439,590
Shares issuable upon the exercise of stock option | shares						790,620
Exercisable weighted-average exercise price (in dollars per share) | $ / shares						$ 9.93
Share Price | $ / shares						$ 44.80
Total value of options						$ 35,418
Value of options excluded from purchase price						18,242
Vested stock options reflected as purchase consideration						17,176
Transaction costs												7,700	$ 4,124
Goodwill deductible for tax purposes												50,428
Revenue												346,641
Net income (loss)						2,222						(196,919)
Unrecognized tax benefit						$ 1,861
Principal assumptions
Stock price | $ / shares						$ 53.31
Strike price | $ / shares						$ 9.93
Volatility						75.93%
Expected term						3 years 18 days
Risk-free rate						0.62%
Envigo RMS Holding Corp | Customer Relationships
BUSINESS COMBINATIONS
Intangible assets												$ 251,000
Weighted-average estimated useful life												12 years 6 months
Envigo RMS Holding Corp | Intellectual property
BUSINESS COMBINATIONS
Intangible assets												$ 49,000
Weighted-average estimated useful life												8 years 9 months 18 days
Robinson Services, Inc.
BUSINESS COMBINATIONS
Consideration in cash					$ 3,250
Shares issued | shares					70,633
Common shares value					$ 2,898
Robinson Services, Inc. | Customer Relationships
BUSINESS COMBINATIONS
Weighted-average estimated useful life												7 years 6 months
Integrated Laboratory Systems, LLC (ILS)
BUSINESS COMBINATIONS
Consideration in cash				$ 38,993
Cash and equivalents assumed												$ 797
Escrowed amount				$ 3,800
Shares issued | shares				429,118
Common shares value				$ 14,466
Settlement of a preexisting relationship				$ (15)
Intangible assets												22,300
Revenue												16,881
Net income (loss)												$ 1,075
Integrated Laboratory Systems, LLC (ILS) | Customer Relationships
BUSINESS COMBINATIONS
Weighted-average estimated useful life												9 years
Orient BioResource Center, Inc
BUSINESS COMBINATIONS
Consideration in cash			$ 26,522
Cash and equivalents assumed												$ 5,481
Shares issued | shares			677,339
Common shares value			$ 18,410
Settlement of a preexisting relationship			$ 1,017
Period for payment of consideration			18 months
Liabilities incurred			$ 3,325
Gain or loss on settlement			$ 0
Intangible assets												13,400
Goodwill deductible for tax purposes												$ 0
Weighted-average estimated useful life												10 years 1 month 6 days
Revenue												$ 35,726
Net income (loss)												5,808
Histion LLC Acquisition
BUSINESS COMBINATIONS
Consideration in cash		$ 950
Shares issued | shares		17,618
Common shares value		$ 364
Principal amount		$ 433
Protypia, Inc.
BUSINESS COMBINATIONS
Consideration in cash	$ 9,460
Shares issued | shares	74,997
Common shares value	$ 806
Principal amount	$ 600
Intangible assets												9,600
Goodwill deductible for tax purposes												$ 0
Protypia, Inc. | Intellectual property
BUSINESS COMBINATIONS
Weighted-average estimated useful life												8 years 4 months 24 days